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Intravenous thrombolytic therapy given early in acute myo-
cardial infarction has been shown to reduce mortality by
approximately 27% (1-4) . The mechanisms for this reduc-
tion are speculative and include myocardial salvage, preser
vation of ventricular function, reduced incidence of ventric-
ular rupture, cnhaiv.;ed healing, amelioration of deleterious
remodeling, improved myocardial electrical stability and
unknown long-term effects of a patent infarct-related coro-
nary artery (5-15) . In addition, it is increasingly becoming
apparent that the following three factors are essential for
mortality reduction .
1) The establishment of early anterograde blood flow in
the infarct-related coronary artery . Although recent data
indicate a marginal survival benefit in patients treated 6 to
12 h after onset of infarction, meaningful clinical survival is
obtained in patients treated within 6 h after onset (1,2,16-
18). Moreover, if therapy can be initiated within I h after
onset, mortality reduction can be -50% and infarcts can be
modified significantly if not actually aborted in some cases
(1,19-21) .
2) Quality of oterograde blood flow in the infarct-related
coronary artery . Recent data (22-24) indicate that patients in
whom complete anterograde blood flow, as defined by
prompt filling of the distal coronary artery (i .e ., so-called
Thrombolysis in Myocardial Infarction [TINA] grade 3 flow),
is achieved after thrombolysis have significantly greater
clinical benefit than do patients who have slower blood flow
(TIMI grade 2 flow) or no flow (TIMI grade 0 or I flow) after
brombolysis .
3) Sustained patency of the infarct-related coronary
artery . It is estimated (25,26) that 10% to 30% of patients
with initial recanalization will have reocclusion during the
hospital stay
. These patients, as well as those patients who
never have recanalization, have an increased mortality rate
during and after the hospital period (14,15,26,27).
Assessing efficacy of thrombolytic therapy. Thus, if we
assume that early infarct-related coronary artery opening,
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complete anterograde flow through the artery and sustained
patency of the artery are variables of immense importance
for efficacy of thrombolytic therapy, can we employ non-
invasive methods to assess their presence or absence during
the early phase of myocardial infarction management? The
answer is a partial yes, for at least the first variable . The
traditional noninvasive markers of infarct-related coronary
artery patency after thrombolysis, including rapid resolution
of ST segment elevation on the electrocardiogram (ECG),
reperfusion arrhythmias, sudden resolution of conduction
disturbances on the ECG, early appearance and peaking of
cardiac enzyme levels, early pyrophosphate uptake by scin-
tigraphy and response of chest pain to therapy, have been
studied (28-36) . Complete resolution of the elevated ST
segment on ECG and complete resolution of chest pain
during thrombolytic therapy correlate well with infarct-
related coronary artery paWncy at early angiography with
patency rates of 96% and 84%, respectively . Unfortunately,
these two clinical events occur in only 6% and 29% of treated
patients during the 1st 91) min of therapy (35) . Partial
resolution of ST segment elevation and partial resolution of
chest pain occur more frequently during thrombolytic ther-
apy and the correlation with infarct-related coronary artery
patency is not as good (34,35) . The presence of reperfusion
arrhythmias, which occur in approximately one third of the
patients during thrombolytic therapy, predictss a 75% to 85%
likelihood of a patent infarct-related coronary artery at early
angiography (33-36) .
Current study . The study by Christian and associates
(37) in this issue of the Journal reexamines the clinical
significance of chest pain in patients with myocardial infarc-
tion undergoing thrombolysis . These workers used a quan-
titative tomographic imaging technique with technetium-99m
sestantibi rather than angiography as the standard for throm-
bolytic efficacy immediately after thrombolysis . The very
slow myocardial washout and minimal redistribution char-
acteristics of this radiotracer are ideal for studies involving
patients with acute myocardial infarction . The image ob-
tained immediately after thrombolysis provides quantitative
data on the nonperfused myocardium, the so-called area
at risk that was present before initiation of therapy and
follow-up studies provide data on ultimate infarct size .
Comparison of the immediate image with the follow-up
image provides estimation of myocardial salvage (38-40) .
There is ample evidence that this method is an adequate
surrogate for the identification of immediate recanalization
of an occluded coronary artery (40,41)
. This method may
even be better than angiography for immediate assessment
of thrombolytic therapy because it obviates the problem of
recurrent coronary occlusion, which will be missed by the
single angiogram
. Arguably, this method provides data on
the three putative ingredients needed for thrombolytic effi-
cacy: early opening, complete flow and sustained coronary
artery patency .
Christian et al






severity just before the start of thrombolytic therapy and
resolution of chest pain during thrombolysis therapy (within
3 h after initiation of recombinant tissue-type plasminogen
activator (rt-PA) infusion or within 1 h after starting strep-
tokinase infusion) were independent predictors of significant
myocardial salvage and final infarct size . Indeed, patients
who had moderate or severe chest pain at the time of
administration of thrombolytic therapy and complete reso-
lution of pain during thrombolysis had salvage of 79% to 89%
of the area at risk in contrast to salvage of 32% of the area at
risk in patients with mild pain and partial or no response to
therapy, These data are in agreement with our current
concepts of the mechanism of chest pain during myocardial
infarction. The chest pain of acute myocardial infarction is
highly variable in quality, intensity and duration . It is
thought to represent the stimulation of afferent sympathetic
nerve endings and perhaps scattered vagal afferent nerve
endings by mediators released from ischemic but viable
myocardium that borders the wave of necrosis (42) . It is
generally accepted that ongoing chest pain indicates ongoing
ischemia and potential for infarct modification by interven-
tion. It is likely that the resolution of chest pain during
thrombolysis as observed in the study of Christian et al . (37)
represented restoration of nutrient blood flow into the isch-
emic zone and alleviation of ischemia .
One surprising finding was reported, The investigators
found a small but significant degree of myocardial salvage
(11%) in patients who were free of chest pain at the time of
thrombolysis. Wit',in reason, some physicians might be
tempted to :vithoolu thrombolytic treatment to this group of
patients. The mechanisms for the apparent myocardial sal-
vage are speculative but may include several possibilities :
1) Spontaneous recanalization was occurring at the time of
the patients' study entry ; 2) recruitment of effective collat-
eral blood' flow was readily available ; and 3) heightened pain
threshold secondary to patient factors or to pharmacologic
interventions or both, was operative .
Lhmltntious of the study. As with all small retrospective
studies, it is possible that selection bias may have entered
the data analysis. For example, quantification of chest pain
was made by chart review . A better prospective study would
have used a patient visual analog scale for pain assessment,
a method that is reasonably reproducible (43) . Moreover, the
authors did not report the time interval from initiation of
thrombolytic therapy to complete resolution of chest pain . In
a recent prospective study, Shah and co-workers (36) found
that in patients with patent infarct-related coronary arteries
after thrombolysis, the onset of a rapid and progressive
resolution of chest pain was not observed for an average of
51 ± 20 min after initiation of an intravenous infusion of
rt-PA. An additional 24 .23 min (range 3 to 50) then elapsed
before chest pain completely resolved
. Additionally, Chris-
tian Ct al, did not evaluate the phenomenon of a sudden
increase in chest pain severity that sometimes heralds the
onset of reperfusion in patients receiving intravenous throm-
bolytic therapy (36,44)
. The obvious problem of concomitant
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drug therapy that could have altered pain threshold and
myocardial ischemia may or may not have been mitigated by
the equal distribution of usage of morphine, beta-adrenergic
blocking agents and nitrate among the subgroups analyzed
(45) . It should be emphasized that resolution of chest pain
during thrombolytic therapy does not guarantee myocardial
salvage at follow-up; a mechanical revascularization proce-
dure coronary angioplasty was required to possibly preserve
myocardial salvage in 18 (29%) of the 62 study patients who
experienced recurrent chest pain during their hospital stay .
Finally, 92% of the patients in the current study received
thrombolytic therapy within 6 It after onset of infarction .
Accordingly, one should not extrapolate the findings of the
study to patients presenting >6 h after onset of infarction, in
whom myocardial salvage is less likely to occur ; this is
especially pertinent to patients presenting late with their
chest pain resolved.
Summary. The study by Christian et al . (37) provides
useful clinical information for the management of the patient
with myocardial infarction with thrombolytic therapy .
1) Complete resolution of chest pain during the infusion of
an intravenous thrombolytic agent suggests reperfusion and
myocardial salvage . Initial conservative medical manage-
ment should be considered in these patients especially if
serial ECGs show a progressive and rapid downward defec-
tion of the ST segment .
2) Patients presenting within 6 h after the onset of
infarction, who are pain free, may still benefit from throm-
bolysis if their ECGs show persistent ischemia .
3) In the remaining patients in whom chest pain does not
resolve completely during thrombolytic therapy, manage-
ment, whether continued medical or invasive strategy,
should be individualized and dictated by the extent of
myocardium at risk (i .e ., by the number of ECG leads
showing ST segment elevation), the response of the ST
segment to thrombolysis and, most important, the clinical
status of the patient .
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